Status:
COMPLETED
Cancer Health Assessments Reaching Many
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
National Human Genome Research Institute (NHGRI)
University of Washington
Conditions:
Hereditary Cancer Syndrome
Eligibility:
All Genders
18-49 years
Phase:
NA
Brief Summary
The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at ri...
Detailed Description
Aim 1. Implement a hereditary cancer risk-assessment program in healthy 18-49-year-old adults in primary care settings, with stakeholder input, and offer exome sequencing to clarify risk. Aim 1A. Ide...
Eligibility Criteria
Inclusion
- Kaiser Permanente Northwest or Denver Health patient
- Screens as high risk for a hereditary cancer syndrome via the risk assessment tool algorithms OR have unknown family history on either their mother or father's side of the family (or both)
- No known prior testing for familial mutations predisposing them to Lynch syndrome or hereditary breast and ovarian cancer
- English or Spanish speaker
Exclusion
- Participant self-reported prior testing for Lynch syndrome (LS) or Hereditary Breast and Ovarian Cancer (HBOC) syndrome or identified as having previous comprehensive testing via Kaiser Permanente data files
- Not an English or Spanish speaker
- Unable to provide informed consent
- Don't want results placed in their medical record
Key Trial Info
Start Date :
August 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2022
Estimated Enrollment :
967 Patients enrolled
Trial Details
Trial ID
NCT03426878
Start Date
August 15 2018
End Date
February 1 2022
Last Update
September 11 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Denver Health
Denver, Colorado, United States, 80204
2
Kaiser Permanente Center for Health Research
Portland, Oregon, United States, 97227